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Calf Spleen Extractive Injection (CSEI), a small peptides enriched extraction, performs immunomodu-
latory activity on cancer patients suffering from radiotherapy or chemotherapy. The present study aims
to investigate the anti-hepatocellular carcinoma effects of CSEI in cells and tumor-xenografted mouse
models. In HepG2 and SMMC-7721 cells, CSEI reduced cell viability, enhanced apoptosis rate, caused
reactive oxygen species (ROS) accumulation, inhibited migration ability, and induced caspases cascade
and mitochondrial membrane potential dissipation. CSEI signiﬁcantly inhibited HepG2-xenografted tu-
mor growth in nude mice. In cell and animal experiments, CSEI increased the activations of pro-apoptotic
proteins including caspase 8, caspase 9 and caspase 3; meanwhile, it suppressed the expressions of anti-
apoptotic protein B-cell lymphoma 2 (Bcl-2) and anti-oxidation proteins, such as nuclear factor-erythroid
2 related factor 2 (Nrf2) and catalase (CAT). The enhanced phosphorylation of P38 and c-JunN-termi-
nalkinase (JNK), and decreased phosphorylation of extra cellular signal-regulated protein kinase (ERKs)
were observed in CSEI-treated cells and tumor tissues. CSEI-induced cell viability reduction was signif-
icantly attenuated by N-Acetyl-L-cysteine (a ROS inhibitor) pretreatment. All data demonstrated that the
upregulated oxidative stress status and the altered mitogen-activated protein kinases (MAPKs) phos-
phorylation contributed to CSEI-driven mitochondrial dysfunction. Taken together, CSEI exactly induced
apoptosis in human hepatocellular carcinoma cells via ROS/MAPKs dependent mitochondrial pathway.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Hepatocellular carcinoma (HCC), the sixth common type of
cancer, threatens humans' life and health worldwide. Patients
suffered fromHCC are often diagnosed with severely impaired liver
function at a late stage and die within 7e8 months after diagnosis
(1). Although multiple therapeutic options have been applied inn University, Changchun City,
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d/4.0/).clinic, adverse effects including immune system disorders and liver
dysfunction are noted in patients (2). Novel therapeutic agents with
lower toxicity for HCC curing are urgently needed.
It has been reported that peptides, either synthetic or derived
from natural products, show anti-hepatocellular carcinoma activ-
ities in animalmodels or clinical trials (3). A small molecular weight
of polypeptide with low toxicity can readily penetrate the tumor
cells without drug resistance (4). Bombesin, a 14-amino acid pep-
tide originally isolated from the skin of the European ﬁre-bellied
toad (Bombina bombina), signiﬁcantly inhibits the growth on SK-
Hep-1-xenografted tumor in nude mice (5). Calf Spleen Extractive
Injection (CSEI), a small peptides enriched extraction, has been
used to ameliorate thrombocytopenia and leucopenia in cancer
patients who underwent chemotherapy and radiotherapy in China
(6, 7). Additionally, efﬁcacious therapy of CSEI combined withnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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from clinical observation suggested by the signiﬁcantly increase of
leukocyte and platelets in blood (8). In our group, CSEI has been
proved to improve immune function in cyclophosphamide-induced
immunosuppressed mice model via NF-kB signaling pathway (9).
As a marketable drug, although occupational therapists have
claimed that CSEI possesses anti-tumor activities, no studies sys-
tematically reported these effects.
Amount of anticancer agents can successfully induce cancer cell
apoptosis, which is recognized as an orderly cell autonomous death
mediated by caspases cascade and mitochondrial dysfunction
(10,11). The over-generation of reactive oxygen species (ROS) can
modulate mitochondrial depolarization (12), and lead to cellular
oxidative stress-induced apoptosis through c-Jun-N-terminal ki-
nase (JNK), P38 and extra cellular signal-regulating kinases (ERKs)
signaling pathways (13e15). Oxidation-reduction system is
destroyed in tumor cells, and high levels of oxidative stress cause
the oxidative modiﬁcation of amino acid residues thereby inducing
DNA mutations and cell apoptosis, therefore, antioxidant agents
could interferewith carcinogenesis (16). In addition, nuclear factor-
erythroid 2 related factor 2 (Nrf2) and catalase (CAT) are two
important factors in apoptosis resistance associated with ROS level
(17, 18). Nrf2 plays a critical role in cellular redox homeostasis by
attenuating oxidative-stress-associated pathological phenomena
(19), and shows mutual inhibition relationship between ROS (20).
Collectively, we hypothesize that CSEI may display anti-cancer
effects via oxidative stress related apoptotic pathway. To verify
this hypothesis, in the present study, the anti-hepatocellular car-
cinoma activity of CSEI in HepG2 and SMMC-7721 cells is examined
systematically, and ROS-related signalings are detected to further
explore its underlying mechanisms.
2. Materials and methods
2.1. CSEI information
CSEI was supplied by JiLin AoDong Pharmaceutical Co., Ltd. in
China, and is a makeable drug in China with the STATE MEDICAL
PERMITMENT No. H22026121. CSEI is a small peptides enriched
extraction, which is separated and puriﬁed from spleen of healthy
cows within 24 h after birth with the peptide concentration of
2.5 ± 0.2 mg/ml. The characteristic spectrum of CSEI analyzed by
high performance liquid chromatography combined with UV de-
tector was displayed as Fig.1S. In our primary experiments, we have
conﬁrmed the safety of CSEI in an acute toxicity test indicating by
no signiﬁcant effects on body weights of Sprague Dawley rats (Tab
S1). CSEI showed strong cytotoxic effects on lung carcinoma cells
(A549), and breast carcinoma cells (MDA and T47D) (Fig. 2S).
2.2. Cell culture
Human HCC tumor cell lines HepG2 and SMMC-7721, and hu-
man embryonic kidney cell line HEK 293T obtained from Shanghai
Cell Collection (Chinese Academy of Sciences, Beijing, China) were
cultured in Dulbecco's Modiﬁed Eagle Media (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 100 units/ml penicillin
and 100 g/ml streptomycin under a humidiﬁed atmosphere con-
taining 5%/95% CO2/air at 37 C. Cell culture reagents were obtained
from Gibco BRL (Grand Island, NY, USA).
2.3. MTT assay
HepG2, SMMC-7721 and HEK 293T were seeded into 96 well
plates at density of 1  104 cells/well. After incubation with
0e1.5 mg/ml CSEI for 24 h, 3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT; SigmaeAldrich, USA) at a ﬁnal
concentration of 0.1 mg/ml was added to each well following an
additional culture at 37 C in darkness for 4 h. In the late incubation,
culture medium was removed, and 100 ml of DMSO was added to
dissolve formazan crystals within cells. The absorbance was
measured using Synergy™4 Microplate Reader (BioTek In-
struments, Winooski, VT) at a wavelength of 490 nm.
In another separate test, 5 mM of N-Acetyl-L-cysteine (NAC; a
ROS inhibitor) was used to pretreat cells for 60 min. After co-
incubation with CSEI for 24 h, cell viability was assessed.
2.4. Colony formation assays
HepG2 and SMMC-7721 cells were seeded into 6 well plate at
density of 3  105 cells/well, and incubated with 0e1.5 mg/ml CSEI
for continuous 7 days. Cells were incubated with 4% para-
formaldehyde for 10 min and stained with 0.05% crystal violet for
60 min. The plate was washed three times with phosphate buffered
saline (PBS), drained upside down on paper towels, and photo-
graphed. The experiment was repeated for six times.
2.5. Migration assay
HepG2 and SMMC-7721 cells were plated in 6 well plates,
cultured to over 90% conﬂuence, and then scraped with a syringe
needle. After 24-h culture with CSEI (0, 0.35 and 0.70 mg/ml), the
distances of migrating cells were used to evaluate the cell migra-
tory ability. The width of the wound was expressed as a percentage
of 0 mg/ml CSEI-treated cells.
2.6. Hoechest 33258 staining
Hoechest 33258, a blue ﬂuorescent dye, could penetrate the cell
membrane and speciﬁcally bind to DNA to show the form of
chromatin; therefore, it is typically used to visualize the apoptotic
nuclei (21). Cells were seeded at 3  105 cells/well in 6 well plates
and incubated overnight. After treatment with CSEI for 24 h, cells
were ﬁxed with 4% paraformaldehyde for 10 min and then stained
with Hoechest 33258 (1 mg/ml) in darkness for 15 min. The samples
were examined via Nikon Eclipse TE 2000-S ﬂuorescence micro-
scope. The relative ﬂuorescence intensity was analyzed by Image J
software (National Institutes of Health, Bethesda, USA).
2.7. Assessment of cell apoptosis
HepG2 and SMMC-7721 cells were seeded into 6 well plates at
4  105 cells per well. After exposure to CSEI for 24 h, cells were
washed with PBS and stained with propidium iodide (PI) and/or
Annexin V at room temperature for 20 min. The intensity of ﬂuo-
rescence was analyzed utilizing Muse™ Cell Analyzer from Milli-
pore (Billerica, MA) following manufacturer's instructions.
2.8. Assessment of caspases activities
Cells treatedwith CSEI for 24 hwere harvested using lysis buffer.
After detecting the protein concentration by BCA Protein Assay Kit
(Millipore, Billerica, MA), the activities of caspase 3, 8 and 9 were
examined according to the protocols of assay kits (Nanjing Jian-
cheng Bioengineering Institute, Nanjing, China).
2.9. Assessment of intracellular ROS levels
20-70-Dichlorodihydroﬂuorescein diacetate (DCFH-DA, Sigma-
eAldrich, USA) staining was used to objectively reﬂect the intra-
cellular ROS level. Cells treated with CSEI for 24 h were suspended
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darkness. After washing with PBS three times, the changes of
intracellular ROS levels were examined via Nikon Eclipse TE 2000-S
ﬂuorescence microscope. Green ﬂuorescence intensity is on behalf
of intracellular ROS accumulation.2.10. Assessment of mitochondrial membrane potential (MMP)
5,50,6,60-tetrachloro-1,10,3,30 tetraethylbenzimidazolylcarbocya-
nine iodide (JC-1; Calbiochem, USA) was used to detect MMP
changes. In normal cells, JC-1 aggregates to form a polymer in the
mitochondrial matrix, and the polymer emits intense red ﬂuores-
cence. In unhealthy cells, JC-1 exists only in the form of a monomer
in the cytoplasm, and it emits green ﬂuorescence (22). HepG2 and
SMMC-7721 cells were seeded into 6 well plates at 3 105 cells per
well and treated with CSEI for 24 h. After incubation with 2 mM of
JC-1 at 37 C for 15min in darkness, the changes of ﬂuorescent colorFig. 1. CSEI induced cytotoxicity in hepatocellular carcinoma cells and showed little effect
7721 (A), but not in HEK 293T (B) after 24-h treatment (n ¼ 6). (C) CSEI inhibited the migrati
Scale bar: 100 mm) (n ¼ 6). Data are expressed as the means ± S.D. *P < 0.05, **P < 0.01 and
carcinoma cells proliferation detecting via crystal violet staining after 7-day treatment (n ¼in the mitochondria were analyzed by ﬂuorescent microscopy via
Nikon Eclipse TE 2000-S ﬂuorescence microscope. The relative red
and green ﬂuorescence intensity was analyzed by Image J software
(National Institutes of Health, Bethesda, USA).2.11. HepG2-xenografted tumor model
5-week-old Male BALB/c nude mice (Chares River Experimental
Animal Technical Co.,Ltd., Beijing, China) were housed in groups of
two in clear plastic cages and maintained on a 12 h light/dark cycle
at 23 ± 1 C with water and food available ad libitum.
The experimental animal protocol was approved by the Animal
Ethics Committee of Jilin University. A total number of
5 106 cells/100 ml was subcutaneously implanted below the right
back near hind leg. 3 days after the cell injection, palpable tumor
size was measured with a caliper. Nude mice were randomly
divided into two groups (n ¼ 6 each). Mice were intraperitoneallyon HEK 293T cells. CSEI dose-dependently reduced cell viability in HepG2 and SMMC-
on ability of hepatocellular carcinoma cells determined via a wound healing assay (10X;
***P < 0.001 versus 0 mg/ml of CSEI-treated cells. (D) CSEI suppressed hepatocellular
6).
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every other day, and the body weight and tumor size were
recorded at the same time. Tumor size was calculated using the
equation length (mm)  (width (mm))2  0.5. After 14-day
treatment, the tumors were harvested and stored at 80 C for
western blot assay.
2.12. Western blot
Cells were planted into 6 well plates at 4  105 cells per well and
treatedwithdoses of CSEI for 24h. Cellswere harvested,washedwith
cold PBS twice and lysed with RIPA buffer (SigmaeAldrich, USA)
containing 1% protease inhibitor cocktail (SigmaeAldrich, USA) andFig. 2. CSEI induced apoptosis in hepatocellular carcinoma cells after 24-h treatment. (A) C
examined by Hoechst 33258 staining (20X; Scale bar: 100 mm). Numerical data were dem
carcinoma cell apoptosis rate analyzed via ﬂow cytometry. Numerical data were demonstrate
of caspase 3, 8 and 9 in HepG2 and SMMC-7721 cells (n ¼ 6). Data are expressed as the me2% PMSF (Phenylmethanesulfonyl ﬂuoride) (SigmaeAldrich, USA).
Similarly, tumors were lysed in the same protocol mentioned above.
The protein concentration was measured by BCA Protein Assay Kit
(Millipore, Billerica, MA) for three times repeated. 40 mg of proteins
were separated using a 10%e12% SDS-PAGE gel and transferred
electrophoretically onto PVDF membranes. The transferred mem-
braneswere blocked in 5% bull serum albumin (BSA) for 4 h, and then
blotted with the following primary antibodies at 4 C overnight at
dilution of 1: 1000: phosphor (P)-ERKs (ab47339), total (T)-ERKs
(ab17942), P-JNK (ab192200), T-JNK (ab1798461), P-P38 (ab31828), T-
P38 (ab31828), cleavedpoly (ADP-ribose) polymerase (cleaved-PARP)
(ab32064), poly (ADP-ribose) polymerase (PARP) (ab32138), Bcl-2
(ab32124), cleaved-caspase 3 (ab2302), cleaved-caspase 8SEI induced nucleus apoptotic morphologic alteration in HepG2 and SMMC-7721 cells
onstrated by the average optical density (n ¼ 6). (B) CSEI enhanced hepatocellular
d by the sum of early and late apoptosis rates (n ¼ 6). (C) CSEI enhanced the activation
ans ± S.D. *P < 0.05, **P < 0.01 and ***P < 0.001 versus 0 mg/ml of CSEI-treated cells.
D. Jia et al. / Journal of Pharmacological Sciences 132 (2016) 122e130126(ab181580), cleaved-caspase 9 (ab2014), Nrf2 (ab62352), CAT
(ab52477)andglyceraldehyde-3-phosphatedehydrogenase (GAPDH)
(ab8245) purchased from Abcam (Cambridge, MA), followed by
treatment with horseradish peroxidase-conjugated secondary anti-
bodies diluted 1:2000 (Santa Cruz, USA). Chemiluminescence was
detectedusingECLdetectionkits (Millipore,USA)and imagingsystem
(Biospectrun 600). The intensity of the bands was quantiﬁed by
scanning densitometry using software Image J (National Institutes of
Health, Bethesda, USA).
2.13. Statistical analysis
All of the experiments were carried out in sextuplicate. All
values were expressed as mean ± S.D. A one-way analysis of vari-
ance (ANOVA) was used to detect statistical signiﬁcance followed
by post-hoc multiple comparisons (Dunn's test) using SPSS 16.0Fig. 3. CSEI caused mitochondrial dysfunction in hepatocellular carcinoma cells after 24-h tr
bar: 100 mm). Numerical data were expressed as the ratio of red to green ﬂuorescence inten
cleaved-PARP, and evidently reduced the levels of Bcl-2 in HepG2 (B) and SMMC-7721 (C
GAPDH (n ¼ 6). Data are expressed as the means ± S.D. *P < 0.05, **P < 0.01 and ***P < 0.software (IBM corporation, Armonk, USA). The value of P < 0.05 was
considered to be signiﬁcant.
3. Results
3.1. CSEI causing cell damage in hepatocellular carcinoma cells
CSEI dose-dependently reduced the cell viability of HepG2 and
SMMC-7721 cells (P < 0.001; Fig. 1A), but showed no signiﬁcant
effects on HEK 293T cells after 24-h treatment (P > 0.05; Fig. 1B).
The 24-h IC50 of CSEI in HepG2 and SMMC-7721 were approxi-
mately 0.70 mg/ml and 0.66 mg/ml respectively. A wound healing
assay was performed to observe the inhibitory effect of CSEI on the
migration ability of hepatocellular carcinoma cells. Compared with
non-treated cells, whose wound areas were almost healed, the
migration ability was strongly inhibited by CSEI (P < 0.01; Fig. 1C).eatment. (A) CSEI induced the dissipation of MMP detected by JC-1 staining (20X; Scale
sity (n ¼ 6). CSEI signiﬁcantly enhanced the expressions of cleaved-caspase 3, 8, 9, and
) cells. Quantiﬁcation data of protein expressions were normalized by corresponding
001 versus 0 mg/ml of CSEI-treated cells.
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mation were apparent at 0.5 mg/ml, and from 1.0 to 1.5 mg/ml of
CSEI, the clonogenic ability was completely blocked (Fig. 1D).3.2. CSEI inducing apoptosis in hepatocellular carcinoma cells
Hoechst 33342 staining corroborated that CSEI at doses of 0.35
and 0.7 mg/ml strikingly induced nucleus apoptosis in hepatocel-
lular carcinoma cells indicated by the enhanced blue ﬂuorescence
intensity (P < 0.01; Fig. 2A). Exposure to CSEI for 24 h signiﬁcantly
increased the early and late apoptosis rate in HepG2 and SMMC-
7721 cells in a dose-dependent manner, and reached the maximum
of 23.97% and 15.53% respectively (P < 0.001; Fig. 2B). The activa-
tion of caspase 3, 8 or 9 is considered as typical events in mito-
chondrial apoptosis (23). CSEI enhanced 14.1%, 26.2% and 9.1%
activities of caspase 3, 8 and 9 in HepG2 cells, respectively (P< 0.05;
Fig. 2C). In SMMC-7721 cells, 32.2%, 6.3% and 22.3% enhancement of
caspase 3, 8, 9 activities were observed in CSEI-treated cells
(P < 0.01; Fig. 2C).Fig. 4. Intracellular ROS accumulation contributes to CSEI-mediated hepatocellular carcinom
and SMMC-7721 cells analyzed via DCFH-DA staining (20X; Scale bar: 100 mm). Numerical d
CSEI treatment reduced the expression of Nrf2 and CAT in HepG2 and SMMC-7721 cells. Q
(n ¼ 6). (C) NAC pretreatment strikingly abrogated CSEI-reduced cell viability (n ¼ 6). Data ar
CSEI-treated cells. ##P < 0.05 and ###P < 0.001 versus 0.35 and 0.70 mg/ml of CSEI-treat3.3. CSEI causing apoptotic alteration on mitochondrial function
Mitochondrial function is one of the factors responsible for cell
apoptosis. 24-h CSEI incubation signiﬁcantly caused MMP loss in
hepatocellular carcinoma cells indicated by the augment in green
ﬂuorescence (JC-1 monomers) and the reduction in red ﬂuores-
cence (JC-1 aggregates) (P < 0.01; Fig. 3A). In CSEI-treated cells, the
expressions of cleaved-caspase 3, 8, 9, which are active forms
inducing cell apoptosis, as well as cleaved-PARP, were enhanced
signiﬁcantly; conversely, the expression of Bcl-2 was suppressed in
HepG2 and SMMC-7721 cells respectively (P < 0.05; Fig. 3B,C).3.4. ROS accumulation being responsible for CSEI-induced
hepatocellular carcinoma cell apoptosis
CSEI caused signiﬁcant intracellular ROS accumulation indicated
by the enhanced green ﬂuorescence in HepG2 and SMMC-
7721 cells (P < 0.05; Fig. 4A). Nrf2 and CAT, two oxidative stress
markers, which could reduce the production of ROS, were selecteda cell apoptosis. (A) CSEI dose-dependently increased intracellular ROS levels in HepG2
ata were demonstrated by the average of green ﬂuorescence density (n ¼ 6). (B) 24-h
uantiﬁcation data of protein expressions were normalized by corresponding GAPDH
e expressed as the means ± S.D. *P < 0.05, **P < 0.01 and ***P < 0.001 versus 0 mg/ml of
ed cells.
Fig. 5. MAPKs activation is involved in CSEI-mediated apoptosis in hepatocellular
carcinoma cells. After 24-h CSEI treatment, the reduced P-ERKs expression and the
enhanced P-JNK and P-P38 expressions were observed in HepG2 and SMMC-7721 cells.
Quantiﬁcation data of P-ERKs, P-JNK and P-P38 expressions were normalized by cor-
responding total protein expressions. Data are expressed as mean ± S.D. (n ¼ 6) and
analyzed using a one-way ANOVA. *P < 0.05, **P < 0.01, and ***P < 0.001 versus 0 mg/
ml of CSEI-treated cells.
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cellular carcinoma cells. CSEI signiﬁcantly reduced the expressions
of Nrf2 and CAT in hepatocellular carcinoma cells (Fig. 4B). Further
data showed that the reduced cell viability caused by CSEI was
strongly abolished via pre-treatment with 1 mM of NAC in HepG2
and SMMC-7721 cells (P < 0.01; Fig. 4C) for 60 min. Data indicated
that CSEI-mediated hepatocellular carcinoma cell apoptosis may be
associated with intracellular ROS accumulation.
3.5. CSEI regulating MAPKs activation in hepatocellular carcinoma
cells
The activation of mitogen-activated protein kinases (MAPKs) is
involved in cell proliferation, differentiation, inﬂammation and
apoptosis (24). CSEI dose-dependently suppressed the phosphory-
lation of ERKs, and enhanced the activities of JNK and P38 in HepG2
and SMMC-7721 cells after 24-h treatment (P < 0.05; Fig. 5).
3.6. CSEI inhibiting HepG2-xenografted tumor growth in nude mice
14-day CSEI treatment at 1.75 mg/kg strikingly suppressed the
HepG2-xenografted tumor growth in nude mice without inﬂu-
encing their bodyweights, suggesting that CSEI is an effective agent
without aggressive side-effects (Fig. 6A, B and D). Compared with
non-treated mice, 29.6% tumor size was decreased in CSEI-treated
mice at the end of the treatment (P < 0.01; Fig. 6C). CSEI
enhanced the expressions of cleaved caspase 3 and cleaved-PARP,
conversely, suppressed the levels of Nrf2 and CAT (P < 0.05;
Fig. 6E). Furthermore, in tumor tissues, CSEI resulted in a 30%
reduction of P-ERKs level, and 30% and 90% enhancement of P-JNK
and P-P38 expression indicating that MAPKs may play important
roles during CSEI-mediated anti-hepatocellular carcinoma
(P < 0.01; Fig. 6F).
4. Discussion
Recently, the incidence and mortality of cancer continue to rise,
especially for the rapid development of hepatocellular carcinoma in
Asia and Africa (25). Due tomulti-target effects and low toxicity, the
multi-component drug has become a research focus. CSEI, widely
used as an adjuvant therapy agent, alleviates chemotherapy-
induced adverse reactions, especially improves immune ability
(26,27). In cyclophosphamide-induced immunosuppressed mice
model, we have successfully conﬁrmed the immunomodulatory
activity of CSEI. Encouragingly, in our present study, the anti-
hepatocellular carcinoma activities of CSEI in human HCC tumor
cells and HepG2-xenografted tumor mouse model were conﬁrmed,
and the roles of ROS-dependent mitochondrial pathway during this
effect were further explored.
CSEI enhanced the dissipation of MMP in hepatocellular carci-
noma cells. Bcl-2, locating in outer mitochondrial membrane, reg-
ulates nucleic mitochondrial membrane permeability and was
reduced by CSEI (28). Bcl-2 expression is known as a hallmark to
detect whether the cell damage related withmitochondria function
(29). Following with MMP reducing, mitochondrial permeability
transition pores (PTP) are opened, which further leads to pro-
apoptotic molecules release; consequently, caspase 3 and PARP
are activated (30). As an apoptotic biomarker, cleaved-PARP
expression was enhanced by CSEI, which may be regulated by
caspase 3 (31). Mitochondria and caspases engage in a self-
amplifying pathway of mutual activation (32). As reported,
cleaved-caspase 8 induces cleavage and activation of Bid acting on
the intrinsic pathway (33). Cytochrome c released from mito-
chondria activates caspase 9 via binding to apoptotic protease
activating factor 1 (Apaf-1) (34,35). Through proteolytic cleavage,caspase 3 is activated by caspase 8 and caspase 9, and then it
cleaves vital cellular proteins or other caspases causing dissection
of DNA molecules and leading to apoptosis (36). Corn peptides
which triggered the activation of cleaved-caspase 3 showed a pro-
apoptotic effect in HepG2 cells (37). The activation of caspase 3, 8
and 9 has been noted in CSEI-induced cell apoptosis suggesting the
roles of mitochondria-dependent intrinsic pathway.
On the other hand, it has demonstrated in amount of studies
that oxidative stress induces apoptosis through DNA damage and
mitochondrial dysfunction (38,39). ROS accumulation contributes
to abnormal changes in mitochondrial membrane permeability
(40). As a positive feedback loop between intracellular ROS and
mitochondria, during mitochondria-dependent apoptosis, a large
amount of ROS is released into cytoplasm (41). NAC, a common ROS
inhibitor, strongly abolished CSEI-reduced cell viability, which
conﬁrmed the central role of ROS. ROS regulates CATand Nrf2 levels
which are usually over-expressed in tumor cells, and promotes Nrf2
to transfer into the nucleus (42). It has been proved that the
reduction of Nrf2 and CAT promotes apoptosis induced by oxidative
stress (43). Therefore, the increased ROS levels and decreased Nrf2
and CAT expression in hepatic carcinoma cells may be responsible
for CSEI-caused apoptosis.
Moreover, ROS accumulation contributes to MAPKs activation
(44,45). ROS inhibits JNK phosphatase and inactivates other po-
tential inhibitory factors to promote tumor cell apoptosis (46). ERKs
and JNK regulate antioxidant response element (ARE) to inﬂuence
antioxidases expressions. Nrf2 could be phosphorylated by P38
inducing strengthen binding with Kelch-like ECH-associated
Fig. 6. CSEI inhibited HepG2-xenografted tumor growth in nude mice. BALB/c athymic nude mice inoculated with HepG2 cells were treated with 0 and 1.75 mg/kg of CSEI for 14
days. Tumor-possessing nude mice (A) and tumor tissues (B) were separated from each mouse. (C) Growth curves of HepG2-xenografted tumors in nude mice. Tumor volumes were
measured every other day. (D) Mean (±S.D.) body weight of 0 and 1.75 mg/kg of CSEI-treated mice. (E and F) CSEI signiﬁcantly enhanced the expressions of cleaved-caspase 3,
cleaved-PARP, P-JNK and P-P38, and evidently reduced the expressions of Nrf2, CAT and P-ERKs in tumor tissues. Quantiﬁcation data of protein expressions were normalized by
corresponding GAPDH and/or total protein expressions, respectively. Data are expressed as mean ± S.D. (n ¼ 6) and analyzed using a one-way ANOVA. *P < 0.05, **P < 0.01, and
***P < 0.001 versus 0 mg/ml of CSEI-treated mice.
D. Jia et al. / Journal of Pharmacological Sciences 132 (2016) 122e130 129protein1 (Keap1), which leads to activity inhibition (47,48). Anti-
oxidants like diallyl sulﬁde or apo-80-lycopenal cause nuclear
translocation of Nrf2 via activation of ERK/P38 (49,50). Arsenic
enhances ROS levels to induce neuronal cell apoptosis via MAPKs-
mediated mitochondrial pathway with a sharp reduction of Nrf2
(47). Since JNK and P38 are reported to inﬂuence mitochondrial
function (51,52), ROSmay serve as a link betweenMAPKs activation
and mitochondrial apoptotic pathway during CSEI-induced hepa-
tocellular carcinoma cell damage.
In conclusion, the anti-hepatocellular carcinoma effect of CSEI in
in vitro and in vivo experiments was conﬁrmed in our study. CSEI
induces ROS accumulation, migration inhibition, caspase cascade,
MMP dissipation and abnormal expression of apoptosis related
proteins. Incremental ROS generation serves as a link between
mitochondrial dysfunction and MAPKs activation. Valuable phar-
macological evidences for CSEI as a potential chemotherapeutic
agent of hepatocellular carcinoma and other primary tumors were
provided in the present study.Conﬂict of interest
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